Case Report: High-grade diffuse leptomeningeal glioneuronal tumor-MC2 in a 6-year-old child with diagnostic delay and short-term complete radiological response after CEV-based chemotherapy

Diffuse leptomeningeal glioneuronal tumor (DLGNT) represents a rare central nervous system neoplasm predominantly observed in pediatric patients. Most cases pursue an indolent clinical course; nevertheless, a small subset demonstrates high-grade histology together with craniospinal dissemination and carries a dismal prognosis. We describe a 6-year-old girl presenting with recurrent vomiting and obstructive hydrocephalus. Initial neuroimaging revealed cerebellar cystic lesions and diffuse leptomeningeal enhancement, which was initially misinterpreted as infectious meningoencephalitis. Tumor biopsy was declined by the patient’s family at initial consultation, and ventriculoperitoneal shunt placement was performed for hydrocephalus relief. One year after shunt surgery, craniospinal magnetic resonance imaging (MRI) documented substantial tumor progression, with corpus callosum infiltration and vertebral body signal abnormalities. Subsequent biopsy established the diagnosis of DLGNT with high-grade histological features, with a Ki-67 proliferation index of approximately 80%. DNA-methylation profiling assigned the tumor to the DLGNT-MC2 molecular subclass. Additional molecular findings included KIAA1549::BRAF gene fusion, 1p deletion, 1q gain, and 17q gain, with an intact 19q and no 1p/19q codeletion. The child received eight cycles of carboplatin, etoposide, and vincristine (CEV) chemotherapy. Nine months after completing treatment, whole-neuroaxis contrast-enhanced MRI (brain and entire spine) showed no residual or recurrent enhancing lesions in either the brain or spine. Neurological function remained stable, and no further seizure episodes occurred. Treatment-related adverse events were confined to grade 2 myelosuppression and mild gastrointestinal intolerance, which were managed by supportive care measures. Our case suggests that risk-adapted CEV chemotherapy may serve as a reasonable upfront therapeutic option for unresectable, aggressive MC2-subtype DLGNT, achieving a short-term complete radiological response. Extended clinical and radiological surveillance is mandatory to validate long-term disease control.

Authors

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-13
DOI
https://doi.org/10.3389/fonc.2026.2015592
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Case Report: High-grade diffuse leptomeningeal glioneuronal tumor-MC2 in a 6-year-old child with diagnostic delay and short-term complete radiological response after CEV-based chemotherapy

Yongkang Zhang, Wangbin Deng, Guofu Li
2 links
Frontiers in Oncology
Glioma Diagnosis and Treatment
article

Case Report: High-grade diffuse leptomeningeal glioneuronal tumor-MC2 in a 6-year-old child with diagnostic delay and short-term complete radiological response after CEV-based chemotherapy

Yongkang Zhang, Wangbin Deng, Guofu Li
article en

Abstract

Diffuse leptomeningeal glioneuronal tumor (DLGNT) represents a rare central nervous system neoplasm predominantly observed in pediatric patients. Most cases pursue an indolent clinical course; nevertheless, a small subset demonstrates high-grade histology together with craniospinal dissemination and carries a dismal prognosis. We describe a 6-year-old girl presenting with recurrent vomiting and obstructive hydrocephalus. Initial neuroimaging revealed cerebellar cystic lesions and diffuse leptomeningeal enhancement, which was initially misinterpreted as infectious meningoencephalitis. Tumor biopsy was declined by the patient’s family at initial consultation, and ventriculoperitoneal shunt placement was performed for hydrocephalus relief. One year after shunt surgery, craniospinal magnetic resonance imaging (MRI) documented substantial tumor progression, with corpus callosum infiltration and vertebral body signal abnormalities. Subsequent biopsy established the diagnosis of DLGNT with high-grade histological features, with a Ki-67 proliferation index of approximately 80%. DNA-methylation profiling assigned the tumor to the DLGNT-MC2 molecular subclass. Additional molecular findings included KIAA1549::BRAF gene fusion, 1p deletion, 1q gain, and 17q gain, with an intact 19q and no 1p/19q codeletion. The child received eight cycles of carboplatin, etoposide, and vincristine (CEV) chemotherapy. Nine months after completing treatment, whole-neuroaxis contrast-enhanced MRI (brain and entire spine) showed no residual or recurrent enhancing lesions in either the brain or spine. Neurological function remained stable, and no further seizure episodes occurred. Treatment-related adverse events were confined to grade 2 myelosuppression and mild gastrointestinal intolerance, which were managed by supportive care measures. Our case suggests that risk-adapted CEV chemotherapy may serve as a reasonable upfront therapeutic option for unresectable, aggressive MC2-subtype DLGNT, achieving a short-term complete radiological response. Extended clinical and radiological surveillance is mandatory to validate long-term disease control.

Frontiers in OncologyVol. 16
Good health and well-being
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon